Please assess the completion status of the following clinical trial:

Trial Title: MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients between 18 - 75 years~* Recipients of single-organ renal primary allograft or second renal transplants (provided that the previous graft was not lost from acute rejection within the first year) from living or cadaver donors~* Patients who provide written informed consent.~Exclusion Criteria:~* PRA \> 20% within 6 months prior to enrollment~* Cold ischemia time \> 30 hours~* Previous treatment with daclizumab~* History of malignancy (except localized skin cancer)~* Active peptic ulcer disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).